ArticleCureus2025
Clinical and Serological Profile of Myasthenia Gravis in the O'Higgins Region of Chile: A Regional Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myasthenia gravis (MG) is a rare, chronic, and progressive autoimmune disorder that can lead to significant disability in its advanced stages. This retrospective observational study aimed to estimate the prevalence of MG in the O'Higgins Region of Chile and provide a comprehensive characterization of patients' clinical profiles, including medical history, diagnostic findings, and therapeutic responses. A female predominance (n=47, 66.2%) was observed, and most patients showed abnormalities in electrophysiological studies. In nearly all cases, diagnosis was established through autoantibody testing, with acetylcholine receptor antibodies being the most frequently identified. The most frequent comorbidities included mood disorders, hypertension, and thyroid dysfunction. Most patients received cholinesterase inhibitors; corticosteroids were used in 74.6% of cases, and one-third were treated with conventional immunosuppressants. A smaller group received biological therapies such as rituximab or other newer agents, ravulizumab. Despite the range of available treatments, approximately 20% of patients exhibited a refractory disease course. MG is a disease with a multifaceted impact on patients' personal, social, and occupational lives. The findings of this study may support the development of targeted health policies aimed at improving comprehensive care for MG patients in Chile.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.